Search

Displaying results 191 - 200 of 135872 in total
  1. Pathway

    Nadroparin Action Pathway

    smpdb.ca/view/SMP0126171
    Drug action

    Its mechanism of action after subcutaneous administration causes it to bind to antithrombin III and inactive factor Xa. … The inactivation of factor Xa halted the conversion of prothrombin to thrombin and also halts the conversion of fibrinogen.

    Drugs: Calcium · Nadroparin
    Enzymes: Fibrinogen beta chain, Fibrinogen alpha chain
  2. Pathway

    Tinzaparin Action Pathway

    smpdb.ca/view/SMP0126174
    Drug action

    It can interact with herbs and supplements, so avoid those with anticoagulants and antiplatelet activity such as garlic, ginger, bilberry, danshen, piracetam and ginkgo bilba. … Through the liver, it is metabolized through sulfation and polymerization and is eliminated through the kidneys.

    Drugs: Calcium
    Enzymes: Fibrinogen beta chain, Fibrinogen alpha chain
  3. Pathway

    Eptifibatide Action Pathway (new)

    smpdb.ca/view/SMP0126461
    Drug action

    It is administered intravenously and can act to decrease platelet aggregation for up to two days after administration. … The conformational change also prevents the binding of the von Willebrand factor to the platelets, which also prevents aggregation and adhesion.

    Drugs: Eptifibatide · Von Willebrand factor human
    Enzymes: Fibrinogen alpha chain, Fibrinogen beta chain
  4. Pathway

    Sunitinib Action Pathway

    smpdb.ca/view/SMP0126868
    Drug action

    Sunitinib also affects RET, CSF-1R, and flt3 RTKs. … Sunitinib is a chemotherapeutic agent and receptor tyrosine kinase inhibitor utilized in the treatment of renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST).

    Drugs: Sunitinib · Calcium
    Enzymes: Fibrinogen beta chain, Fibrinogen alpha chain
  5. Pathway

    Midostaurin Action Pathway

    smpdb.ca/view/SMP0126900
    Drug action

    By inhibiting these kinases, Midostaurin disrupts signaling cascades that lead to malignancies such as AML and ASM, ultimately inducing apoptosis in leukemia cells and mast cells. … Its mechanism of action involves targeting multiple receptor tyrosine kinases, including protein kinase C alpha (PKCalpha), VEGFR2, KIT, PDGFR, and WT and/or mutant FLT3 tyrosine kinases.

    Drugs: Calcium · Midostaurin
    Enzymes: Fibrinogen beta chain, Fibrinogen alpha chain
  6. Pathway

    Regorafenib Action Pathway

    smpdb.ca/view/SMP0126907
    Drug action

    Regorafenib functions as an inhibitor of multiple kinases, playing a role in normal cellular processes and pathological conditions like oncogenesis, tumor angiogenesis, and the maintenance of the tumor … Regorafenib is an oral kinase inhibitor with a broad spectrum of activity. It is used to treat metastatic colorectal cancer, advanced gastrointestinal stromal tumors, and hepatocellular carcinoma.

    Drugs: Calcium · Regorafenib
    Enzymes: Fibrinogen beta chain, Fibrinogen alpha chain
  7. Pathway

    Tivozanib Action Pathway

    smpdb.ca/view/SMP0126910
    Drug action

    In preclinical studies using mice and rats, tivozanib demonstrated its ability to inhibit tumor angiogenesis, slow tumor growth, and reduce vascular permeability. … In the UK and some other countries, it is indicated as the first-line therapy for adults with advanced RCC who have not previously received VEGFR and mTOR pathway inhibitors after their disease has progressed

    Drugs: Calcium · Tivozanib
    Enzymes: Fibrinogen beta chain, Fibrinogen alpha chain
  8. Pathway

    Heparin

    smpdb.ca/view/SMP0130950
    Physiological

    Specifically it is also used in the treatment of heart attacks and unstable angina. … Heparin acts as an anticoagulant, preventing the formation of clots and extension of existing clots within the blood.

    Drugs: Heparin · Calcium
    Enzymes: Fibrinogen beta chain, Fibrinogen alpha chain
  9. Pathway

    Tranexamic Acid Action Pathway (New)

    smpdb.ca/view/SMP0124487
    Drug action

    In the presence of calcium, the active site transitions and a TF-VIIa complex is formed. This complex aids in activation of factors IX and X. … The clotting process consists of two pathways, intrinsic and extrinsic, which converge to create stable fibrin which traps platelets and forms a hemostatic plug.

    Drugs: Tranexamic acid · Calcium
    Enzymes: Fibrinogen beta chain, Fibrinogen alpha chain
  10. Pathway

    Apixaban Action Pathway (new)

    smpdb.ca/view/SMP0126437
    Drug action

    Used in the treatment and prevention of recurrent thromboembolic diseases, such as deep vein thrombosis and pulmonary embolisms. … Apixaban is metabolized by both CYP3A4 and P-glycoprotein (P-gp) and is known to increase in the blood when these are inhibited.

    Drugs: Calcium · Apixaban
    Enzymes: Fibrinogen beta chain, Fibrinogen alpha chain